Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs — Stella

Home/Hepatitis C, Chronic/

View on ClinicalTrials.gov

Recruiting

Back to Hepatitis C, Chronic trials

Trial locations(1 site)

Pakistan

Aga Khan University, Karachi

Key details

Sponsor

Queen Mary University of London

Collaborators

Aga Khan University, Dow University of Health Sciences

Enrollment target

~25,000 participants

Started

November 2021

Primary completion

January 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 100 Years

Last updated March 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.